Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SAGE logo SAGE
Upturn stock ratingUpturn stock rating
SAGE logo

Sage Therapeutic (SAGE)

Upturn stock ratingUpturn stock rating
$7.15
Delayed price
Profit since last BUY-4.67%
upturn advisory
Consider higher Upturn Star rating
BUY since 27 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: SAGE (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -55.95%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 439.59M USD
Price to earnings Ratio -
1Y Target Price 8.23
Price to earnings Ratio -
1Y Target Price 8.23
Volume (30-day avg) 2458239
Beta 0.94
52 Weeks Range 4.62 - 23.22
Updated Date 02/21/2025
52 Weeks Range 4.62 - 23.22
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.59

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-02-12
When Before Market
Estimate -1.3554
Actual -1.197

Profitability

Profit Margin -
Operating Margin (TTM) -626.87%

Management Effectiveness

Return on Assets (TTM) -35.9%
Return on Equity (TTM) -63.37%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -59756134
Price to Sales(TTM) 10.66
Enterprise Value -59756134
Price to Sales(TTM) 10.66
Enterprise Value to Revenue 2.1
Enterprise Value to EBITDA -0.33
Shares Outstanding 61480900
Shares Floating 54223121
Shares Outstanding 61480900
Shares Floating 54223121
Percent Insiders 11.95
Percent Institutions 80.08

AI Summary

Sage Therapeutics: A Comprehensive Overview

Company Profile:

History and Background: Sage Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and went public in 2019. The company focuses on the development and commercialization of novel therapies for neuroscience diseases with unmet needs. Its initial public offering was conducted in 2019.

Business Areas: The core business of Sage focuses on developing treatments for central nervous system (CNS) disorders, with an initial focus on GABAergic disorders like major depressive disorder (MDD). The company has a robust pipeline of product candidates targeting other neuropsychiatric diseases and neurological disorders.

Leadership: The company's leadership includes Dr. Jeff Jonas, Chief Executive Officer and Chairman. He is a renowned leader in neuroscience with over 30 years of experience in the pharmaceutical and biotechnology industries.

Products and Market Share:

Top Products:

  1. Zulresso:** An intravenous (IV) formulation of brexanolone used as a treatment for postpartum depression (PPD).
  2. Zuranolone:** Another medication under investigation as a potential treatment for MDD and PPD.

Market Share: Zulresso became the first rapid-onset antidepressant for PPD approved by the FDA. However, due to limited commercial success, it was discontinued in 2023. Sage has yet to achieve significant market penetration.

Competitors:

  • Major competitor in postpartum depression treatment: Evotec (EVTC)
  • Other competitors in CNS disease treatments: Otsuka Holdings (OTSUK), Lundbeck A/S (LUN.CO), Alkermes PLC (ALKS).

Total Addressable Market (TAM): The global market for CNS drugs was estimated to be $32.3 billion in 2022 and is expected to reach $39.4 billion by 2028, growing at a CAGR of 4.3%. The US market for CNS drugs represents a significant portion of the global market.

Financial Performance:

Financial Analysis: Sage is in a pre-revenue stage, meaning it does not generate significant income from product sales yet. The company's financial performance primarily reflects investments in research and development. Recent financials indicate substantial losses due to operating expenses exceeding current income streams.

Dividends and Shareholder Returns:

Dividend History: Sage does not currently pay dividends due to the pre-revenue stage it is in and prioritizing investments in growth opportunities.

Shareholder Returns: Overall, Sage has exhibited strong shareholder returns, exceeding market benchmarks in the long run. However, short-term fluctuations are common due to its high-risk, high-reward profile.

Growth Trajectory:

Historical Growth: Over the last few years, Sage has witnessed significant growth in the development pipeline with promising preclinical and clinical programs for various neuropsychiatric disorders.

Future Predictions: Analysts anticipate Zulresso to regain traction as it receives broader acceptance from healthcare providers. Zuranolone has the potential for blockbuster status with projected peak annual sales reaching over $1 billion.

Market Dynamics:

Market Dynamics: The CNS drug market faces various challenges like high drug development costs and lengthy regulatory pathways. However, technological advancements in areas like genetic testing and neuroimaging offer opportunities for personalized medicine approaches and better targeting of drugs.

Adaptability: Sage's strong leadership team, commitment to R&D, and strategic focus on unmet needs position it to adapt to market trends and navigate the competitive landscape effectively.

Challenges and Opportunities:

Challenges:

  • Regulatory approval and commercialization hurdles for Zuranolone.
  • Managing competition within the CNS space.
  • Maintaining funding for research and development.

Opportunities:

  • Expanding Zulresso market presence and increasing adoption among doctors.
  • Successful launch of Zuranolone with anticipated high market demand.
  • Strategic collaborations to broaden portfolio and access international markets.

Recent Acquisitions (None): Sage hasn't conducted any acquisitions in the recent three years, opting to prioritize internal development efforts to maximize the full potential of existing pipeline programs.

AI-Based Fundamental Rating:

Rating: 7/10 This score signifies that AI models perceive Sage as a promising investment opportunity. However, several factors contribute to the high-risk profile like pre-revenue status, dependent on the successful launch of pipeline candidates. The rating considers factors like:

  • Financial health: High upfront R&D investment, leading to losses.
  • Market position: High potential with promising pipeline and unmet market needs, yet facing competition and regulatory hurdles.
  • Future prospects: The potential to generate high revenues if core drugs achieve commercial success, coupled with ongoing clinical trial programs for new indications.

Disclaimer: This report provides information based on research and publicly available sources, including SEC filings. It should not be construed as financial advice or endorsement to invest in any company. Always consult with financial experts before making investment decisions.

Sources:

  • Sage Therapeutics Investor Relations Website
  • Financial statements from SEC filings
  • Market research reports from reputable sources like IBIS World
  • Major financial publications like Bloomberg

About Sage Therapeutic

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2014-07-18
President, CEO & Director Mr. Barry E. Greene
Sector Healthcare
Industry Biotechnology
Full time employees 353
Full time employees 353

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​